Labcorp EVP, Pres of BLS, CMO & CSO Sold Shares Worth Over $744K

Labcorp Holdings' EVP Brian J. Caveney sold 2,000 shares at $372.04 each, totaling $744,080. He now directly owns 34,562 shares, according to an SEC filing.

Original reporting
Published Nov 12, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Labcorp EVP, Pres of BLS, CMO & CSO Sold Shares Worth Over $744K — source image
Decision brief

The 30-second read

$LHBearishLow
01

Why it matters

The insider sale provides fresh data for investors monitoring insider activity.

02

Market read

A modest insider sell from a senior executive, offering limited trading impetus.

03

What to watch

No change in Labcorp's operational outlook; the sale size is small relative to market cap.

Relevance 5/10Novelty 6/10Timing: same day as filing

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$LHBearishHigh confidence
Context

EVP and CMO of Labcorp sold 2,000 shares for $744,080, reducing his stake to 34,562 shares.

Expected impact

likely slight downward pressure as market prices in the insider sell.

Evidence & confidence

Form 4 filing is a primary source; the sale amount is modest but the insider holds a senior position.

Market effects

Minimal impact on the broader healthcare diagnostics sector.

Limited to U.S. markets where Labcorp trades.

Low global relevance.

Counterpoint

The sale could be routine portfolio rebalancing, not a negative signal.

Key entities

  • Brian J. Caveney

    EVP, President of BLS, CMO & CSO at Labcorp Holdings.

Related articles

$LHHighAI 9/10

Labcorp completes $375M Millennium Health takeover

Labcorp completed its $375M acquisition of Millennium Health, including $245M upfront and up to $130M in milestone payments. The deal aims to enhance Labcorp's toxicology services and expand its geographic reach. Millennium specializes in drug testing, complementing Labcorp's existing offerings. Labcorp CEO Adam Schechter highlighted the strategic fit and growth potential during an earnings call.

$LHMed

Labcorp Finalizes Acquisition of Millennium Health to Expand Toxicology Testing

Labcorp has completed its acquisition of Millennium Health, a specialty lab focused on drug testing and surveillance. The deal aims to expand Labcorp's toxicology testing capabilities nationwide, providing insights for treating chronic pain, substance use disorders, and mental health conditions. Labcorp expects to integrate Millennium's expertise with its own network and digital solutions to improve patient care.

$OPKMed

OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp

OPKO Health Inc (OPK) reported Q3 2026 revenue growth of 16% YoY, driven by product revenue and strong performance from key products. The company expects to receive $722M in cash from the LabCorp transaction, plus up to $150M in royalties. OPK strengthened its balance sheet with $125M in financing and ended the quarter with $403.2M in cash. The company repurchased 7.2M shares for $10.6M.